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Abstract 
 
Doping with growth hormone (GH) is a well-known problem both among elite athletes and 
among people training at gyms. It is mainly the anabolic and, to some extent, lipolytic effect 
of GH that is valued by its users. However, no reliable method to detect GH doping has been 
available, and the role of GH as an effective doping agent has been discussed.  
The aim of this thesis was to investigate markers of the GH/IGF-I axis and specific bone 
markers in athletes in connection with a maximum exercise test and longitudinally for one 
year, to validate the use of these markers in a forthcoming doping test for GH. Furthermore, 
the effects of one month’s administration of supraphysiological GH doses on body 
composition, exercise performance and IGFBP-4 and IGFBP-5 concentrations in well-trained 
healthy subjects were studied. 
The response to a maximum exercise test displayed a fairly uniform pattern, with peak 
concentrations of markers of the GH/IGF-I axis and bone markers immediately after exercise, 
followed by a subsequent decrease to baseline levels. The time to peak value for GH was 
significantly shorter for females compared with males.  
Some of the markers show strong evidence of high inter- or intra-individual variations in 
resting samples during one year, based on analyses focusing on the right tail of the 
distribution in relation to a normal distribution. Post-competition values differed from resting 
values for several of the GH/IGF-I axis and bone markers. Ranges for post competition values 
and for each marker in each gender at specific time points in connection with a maximum 
exercise test, are presented. 
The administration of supraphysiological doses of growth hormone for one month causes a 
dramatic increase in IGF-I levels, a reduction in body fat and an increase in the extracellular 
water volume. However, no significant increase in intracellular water volume was found, 
indicating limited anabolic effects by the supraphysiological GH doses. 
Administration of supraphysiological doses of GH during one month did not improve power 
output or oxygen uptake in a bicycle exercise test.  
Serum levels of IGFBP-4 and IGFBP-5 are increased by supraphysiological GH doses. Some 
of the effect of GH on IGFBP-4 and IGFBP-5 appears to be IGF-I dependent. However, the 
results do not support an obvious role for IGFBP-4 and IGFBP-5 as potential markers in a test 
for detecting GH doping. 
In conclusion, this thesis describes different aspects of markers of the GH/IGF-I axis and 
specific bone markers in connection to rest and exercise, to be used in a forthcoming test for 
GH doping, in which IGFBP-4 and IGFBP-5 do not seem to have a role. Finally, no obvious 
anabolic effects on body composition or performance-enhancing effects were seen with 
supraphysiological GH doses; thus, questioning the role of GH as a potent doping agent. 
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